TRAF3 and metabolic dysfunction-associated steatohepatitis: Cylindromatosis (CYLD), ubiquitin‐specific protease 18 (USP18), and dual‐specificity phosphatase 14 (DUSP14) are reported to be candidate enzymes for suppressing the progression of NASH via inhibiting TAK1,92, 128, 129, 130 whereas the E3 ligase tripartite motif 8, TRAF3, promotes NASH.128, 131, 132, 133 Transcription factors are at the downstream of the intracellular signal pathway and can modulate the expression of effectors that influence the pathogenesis of NAFLD.